Spots Global Cancer Trial Database for Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
Official Title: A Phase II Study of Single-agent Tesetaxel in Chemotherapy-naive Patients Who Have Progressive, Castration-resistant Prostate Cancer
Study ID: NCT01296243
Conditions
Interventions
Study Description
Brief Summary: Given the activity of docetaxel in patients with progressive, metastatic castration-resistant prostate cancer, this study is being undertaken to evaluate the activity of tesetaxel, an orally bioavailable taxane, in chemotherapy-naive and chemotherapy-exposed patients.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
University of Michigan Health System, Ann Arbor, Michigan, United States
The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Contact Details
Name: Michael J Morris, MD
Affiliation: Memorial Sloan Kettering Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
